Mezzion Pharma Co.,Ltd.
Financials
Valuation Metrics
Mezzion Pharma Co.,Ltd.'s Market Cap is ₩1.6T. At end of 2025 it was ₩2.8T. Ranked #226 of 2,405 in KR market (top 9%), #48 of 1,627 on KOSDAQ (top 3%), #20 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.58T KRW | KR#226/2,405 Sec#20/231 |
| Revenue | 8.43B KRW | KR#2,287/2,405 Sec#179/231 |
| Net Income | -27.39B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 125.25B KRW | KR#1,618/2,405 Sec#128/231 |
| Net Assets | 39.04B KRW | KR#2,058/2,405 Sec#183/231 |
| Employees | 18 | KR#2,245/2,405 Sec#213/231 |
| Value | ||
| P/B | 40.57x | KR#2,398/2,405 Sec#230/231 |
| P/S | 187.93x | KR#2,387/2,405 Sec#218/231 |
| FCF Yield | -1.06% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -70.16% | KR#2,306/2,405 Sec#209/231 |
| ROA | -21.87% | KR#2,247/2,405 Sec#180/231 |
| Op. Margin | -223.13% | KR#2,321/2,405 Sec#186/231 |
| Revenue Growth | 6.92% | KR#1,069/2,405 Sec#104/231 |
| Financial Health | ||
| Debt Ratio | 220.79% | KR#2,138/2,405 Sec#221/231 |
| Total Debt | 15.58B KRW | KR#1,478/2,405 Sec#125/231 |
| FCF | -16.73B KRW | KR#1,843/2,405 Sec#175/231 |
| Cash | 40.31B KRW | KR#845/2,405 Sec#52/231 |
| Current Ratio | 0.68x | KR#2,032/2,405 Sec#195/231 |
| Performance | ||
| 1Y Return | -17.12% | KR#1,111/2,405 Sec#74/231 |
| 1M Return | -24.56% | KR#2,078/2,405 Sec#205/231 |
| From 52W High | -71.48% | KR#2,099/2,405 Sec#177/231 |
| 1Y MDD | -70.47% | KR#1,977/2,405 Sec#169/231 |
| Trading | ||
| Volume | 95,950 shares | KR#648/2,405 Sec#68/231 |
| Trading Value | 4.89B KRW | KR#302/2,405 Sec#26/231 |
| Foreign Own. | 24.44% | KR#171/2,405 Sec#7/231 |
| Per Share | ||
| EPS | -887 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,265 KRW | KR#2,242/2,405 Sec#202/231 |
Company Info
Mezzion, established in 2002, is a KOSDAQ-listed pharmaceutical manufacturing and sales corporation. The company develops various new drugs, including treatments for erectile dysfunction and benign prostatic hyperplasia, and has licensed out and exported products to major countries such as the United States. Recently, Mezzion has focused on developing a single ventricle disease treatment, having received FDA approval for an additional clinical protocol in 2023 and currently proceeding with further clinical trials. The company is headquartered in Gangnam-gu, Seoul.